StockData
Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc. (DCOY) stock

DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$0.83−0.04 (-4.68%)

Close on Nov 20, 2026Market cap $543.41KP/E –Yield –

Decoy Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Decoy Therapeutics's gross profit for the twelve months ending Jun 30, 2019 was $1.93M, up 236.5% year over year. For fiscal 2018 it was $1.52M, up 98.0% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2018Dec 31, 2018$1.52M+98.0%
FY2017Dec 31, 2017$767.97K+120.7%
FY2016Dec 31, 2016$347.92K–
FY2015Dec 31, 2015$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2019Jun 30, 2019$859.63K+1211.3%
Q1 FY2019Mar 31, 2019$608.31K+542.7%
Q4 FY2018Dec 31, 2018$88.13K-41.0%
Q3 FY2018Sep 30, 2018$377.11K+42.4%
Q2 FY2018Jun 30, 2018$65.56K-65.5%
Q1 FY2018Mar 31, 2018$94.65K-42.1%
Q4 FY2017Dec 31, 2017$149.49K-9.5%
Q3 FY2017Sep 30, 2017$264.85K-29.9%
Q2 FY2017Jun 30, 2017$190.20K–
Q1 FY2017Mar 31, 2017$163.44K–
Q4 FY2016Dec 31, 2016$165.20K–
Q3 FY2016Sep 30, 2016$377.98K–

More Decoy Therapeutics figures

See a number that looks wrong?